Atb Cap Markets Weighs in on Organigram FY2027 Earnings

Organigram Holdings Inc. (TSE:OGI) – Investment analysts at Atb Cap Markets issued their FY2027 EPS estimates for Organigram in a research report issued to clients and investors on Tuesday, February 11th. Atb Cap Markets analyst F. Gomes anticipates that the company will earn $0.08 per share for the year. The consensus estimate for Organigram’s current full-year earnings is $0.16 per share. Atb Cap Markets also issued estimates for Organigram’s FY2028 earnings at $0.20 EPS.

Several other brokerages also recently issued reports on OGI. Canaccord Genuity Group cut their target price on shares of Organigram from C$3.60 to C$3.15 and set a “speculative buy” rating for the company in a research note on Monday, December 9th. ATB Capital cut their price objective on Organigram from C$5.25 to C$3.50 in a research report on Tuesday, December 17th.

Organigram Stock Performance

Shares of OGI opened at C$1.92 on Thursday. The company has a market cap of C$237.20 million, a PE ratio of -4.06, a price-to-earnings-growth ratio of 0.42 and a beta of 1.13. The firm has a 50-day moving average of C$2.24 and a 200-day moving average of C$2.32. Organigram has a one year low of C$1.86 and a one year high of C$3.95. The company has a debt-to-equity ratio of 3.07, a current ratio of 3.36 and a quick ratio of 2.62.

Organigram Company Profile

Organigram Inc is a Canadian licensed producer of cannabis products. Organigram focuses on producing exceptional, indoor-grown cannabis for patients and adult recreational consumers, as well as developing global business partnerships.